MTBVAC
Phase 3- Indications
- Tuberculosis
Company intelligence / Profile preview
Zendal Group has established itself as a leader in the development and manufacture of biological products—especially vaccines—for both human and animal health. Its subsidiary Biofabri leads the industrial production of COVID antigens for Europe. The group’s TB vaccine candidate MTBVAC has entered large-scale clinical trials with international partners. The company also recently launched the first DNA-based canine leishmaniasis vaccine and commercialized Europe’s first EHD vaccine.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Zendal Group.